Low but Real Risk of Lymphedema Reported After Sentinel Lymph Node Biopsy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 6
Volume 11
Issue 6

EVANSTON, Illinois-Although biopsy of sentinel lymph nodes is often considered an almost risk-free procedure in the staging of breast cancer, a retrospective chart review showed a surprising incidence of lymphedema associated with this procedure. Carole H. Martz, RN, MS, and colleagues at Evanston Northwestern Healthcare in Illinois reported a 3% risk of lymphedema after sentinel lymph node biopsy (SNLB, n = 303), compared to a 17% risk after axillary dissection (n = 117).

EVANSTON, Illinois—Although biopsy of sentinel lymph nodes is often considered an almost risk-free procedure in the staging of breast cancer, a retrospective chart review showed a surprising incidence of lymphedema associated with this procedure. Carole H. Martz, RN, MS, and colleagues at Evanston Northwestern Healthcare in Illinois reported a 3% risk of lymphedema after sentinel lymph node biopsy (SNLB, n = 303), compared to a 17% risk after axillary dissection (n = 117).

"The risk of lymphedema following sentinel node biopsy is low but real and should be treated as such. All patients need to have preoperative education in preventive measures as well as baseline pre-op and post-op arm measurements," Ms. Martz said.

Global recommendations for postoperative lymphedema prevention include weight control, prompt reporting of infection in the limb or breast on the operated side, avoidance of trauma to the arm (such as from blood pressure cuffs, intravenous needles, or vaccinations), and use of a compression garment for airline travel or vigorous exercise.

Retrospective Review

The retrospective chart review of SNLB patients in a clinical research project at Evanston Northwestern Healthcare was prompted by several patients who presented with lymphedema after having SNLB in conjunction with a lumpectomy or mastectomy. Patients’ subjective reports included arm heaviness, arm tightness, rings and clothing feeling tighter, or a change in arm skin and tissue texture or feel.

The investigators pulled all charts on patients who had SLNB either alone or followed by axillary lymph node dissection. "Our initial hypothesis was that there would be no increased risk of lymphedema in the SNLB patients," Ms. Martz said.

Lymphedema was defined as a 1-cm increase in arm circumference compared to preoperative measurements or a 50 mL or greater volumetric measurement difference between arms.

Risk Factors Identified

Chart review identified lymphedema in 9 of 303 SLNB patients (3%) vs 20 of 117 axillary dissection patients (17%). Further analysis uncovered a number of risk factors for lymphedema in SLNB patients. These included:

  • breast tumor located in the upper outer quadrant;

  • breast radiation therapy;

  • axillary radiation;

  • more than one breast operation;

  • weight gain of 10 pounds or more;

  • trauma such as wound infection.

In contrast, there was no association between lymphedema and tumor quadrant location in the axillary dissection patients.

"Our recommendations are that patients who have had either SLNB or axillary dissection should follow standard lymphedema precautions regardless of the number of lymph nodes removed and that clinicians should be aware of the increased risk of lymphedema in patients with upper outer quadrant breast tumors who have had SLNB alone procedures," Ms. Martz said.

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content